Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sup homie? I am all in with C citigroup. Getting ready to make a deposit to buy some REE Rare element.
Hows that little angel of yours? Hope all is well
Word
I have been wayching REE Rare element it has been on a tear, Looks like it"s getting ready for next leg up.
Everything elsce is in C citigroup. Biggest no brainer in the market. I am learning patients pays off.
Had some nice fishing this season. picked up a little boston whaler. had a blast with it.
Hope all is well. Check out REE
Peace
you ever poke your pecker with a pencil? it makes a dot that looks like a blackhead.
I hope you caught the huge reversal here. Unfortunatly, I am not in the game right now. But that was a nice move off it's bottom.
GLTU
Hey, how was your summer? Had a good one myself. Busy hanging on to what I got. No room to gamble. lol
How are you fairing? Hope all is well, and you are making some good trades.
Gorggor
hello folks. long time. I still be holding my shares here. Waiting for another run. It's beginning to smell like it's comming soon. hold on.
Best of luck to all.
Thank you for the heads up Temp, or Amy. What are u liking these days? I have not had much time for trading. I am in a biopharma, ANX no other plays at the moment.
The best to you
I havn't looked at EPG in a while. Was watching for a dead cat bounce. it did that. But i never played it.
I hope you didn't get hurt that bad. I don't like to admit how many times it has happened to me. but is is more than twice. lol
best of luck to ya
good start to the day. Lets take out .32, then we could run if we get a vol. spike
I would think it would be the warrant holders that hire the pumpers?
Still holding my shares for the next leg up. Warrent holders need it higher to sell their shares. They always seem to be able to make it happen. Either by manipulation, I/E using paid pumpers,or the media outlet, or just good old fashioned DD, meaning the warrants were pucrcased for a long time hold because of belief in the company.
IMO we will be going higher soon. In the next few months.
Plan accordingly. And best of luck to all.
IMO 2 reasons we have not tanked.
1 we are not going to get dilution below .37c that is the number in which warrents that are held can be sold.
2 ANX is undervalued on it's potental revenue of their 2 top drug cantidates.
As of right now, my belief is that fair value is at least .50c
again, this is just my opinion.
holding up very well. I am patiently awaiting the next leg up.
theres gotta be another run at .50 here soon. IMO
GLTA
IMGG I shoulda played it. lol I see the MMs trying to hold up ANX. If they can hold it above .34, then more warrants can be sold.
ANX this might be the end for a long while. I am bailing @ .30
I still have good profit locked in there. I won't ride it down any further. There is still good vol.
Fingers crossed it makes another run before it takes a long rest.
IMGG did just what I thought it would
Cmon squeeze this corcksucker. He needs to lose big today.
whatever
I thought Cully was a smart man. Why is he sitting down and doing an interview with this notorious stock killer.
What an IDIOT.
We will be lucky if we don't get killed today, thanks to this article.
Biotech Stock Mailbag: Adventrx Pharmaceuticals
By Adam Feuerstein 01/15/10 - 07:00 AM EST
Loading Comments...
Add CommentStock quotes in this article: ANX , CTIC , CBAI.OB , MNKD , NVLT.OB , HEB WEBSTER CITY, Iowa (TheStreet) -- Welcome back to the Biotech Stock Mailbag. If you're wondering about the Hawkeye dateline, it's because I wrote this column and emailed it to my editor while flying home from the J.P. Morgan Healthcare Conference in San Francisco. Thank you, Virgin America for the free in-flight WiFi!
More on ANX
EnteroMedics, Bionovo: Early Volume PlaysCell Therapeutics Has Strange TimingJackson Hewitt, Cell Therapeutics: Late Day Volume PlaysMarket Activity
ADVENTRX Pharmaceuticals Inc.| ANX DOWNHemispherx Biopharma Inc.| HEB UPCell Therapeutics Incorporated| CTIC DOWNThis Mailbag marks another milestone -- the first reader question sent via Twitter. As I announced last week, I'm now posting biotech stock commentary on my Twitter page at @adamfeuerstein. I hope you'll continue to follow me here and on Twitter, and if you have a biotech stock question for the Mailbag, I now accept email and tweets.
Via Twitter, @dschornnyc asks, "Did you get a chance to see Adventrx Pharmaceuticals(ANX Quote)? Have any thoughts you care to share?"
I attended the Adventrx presentation in San Francisco on Wednesday and spent some time afterward with CEO Brian Culley. Adventrx is a feel-good comeback story in that the company was essentially on life support (and probably should have went under) in 2007 after the failure of its "Co Factor" chemotherapy drug.
Culley deserves credit for somehow managing to keep Adventrx alive. His perseverance paid off last month when the company was able to seek regulatory approval in the U.S. for its first drug candidate, a reformulation of the chemotherapy drug navelbine, known generically as vinorelbine. Adventrx also raised money last week, and with $20 million in total, now has some much-needed breathing room.
Unfortunately, the years Adventrx spent in the wilderness are going to make it difficult for its reformulated chemotherapy drugs to gain traction commercially. These are niche drugs and Adventrx is going to have a tough time making any money selling them.
I know Adventrx looks cheap (share priced around 40 cents cents, a $60 million market cap), but as I'll explain below, I think the company's operating business has some real challenges.
ANX-530 is the name of Adventrx's reformulated vinorelbine currently under FDA review. ANX-530 appears to be bioequivalent to vinorelbine, based on the pharmacokinetic data that formed the basis of the FDA filing. Moreover, Adventrx says ANX-530 causes less vein irritation than vinorelbine when administered to patients.
I have no beef with any of these Adventrx claims. The problem, however, is that ANX-530, if approved in the U.S., is entering a very small commercial market in non-small cell lung cancer where it will have to compete against generic (read: inexpensive) vinrorelbine.
Adventrix chief Culley says the addressable commercial market opportunity for ANX-530 in non-small cell lung cancer is $200 million in the U.S. - but that's a made up number and wildly unrealistic.
Total vinorelbine sales in the U.S. are about $20 million annually, according to research firm IMS Health. That's the real addressable market opportunity for ANX-530.
Culley comes up with $200 million because he commissioned some market research that concluded that doctors would be willing to use ANX-530 over vinorelbine even at ten times the generic price. (Adventrx paid for the market research, so results aren't exactly unbiased.)
In other words, if ANX-530 totally replaced generic vinorelbine in the U.S. and ANX-530 was priced at ten times (!!!) the generic vinorelbine price, Adventrix could generate $200 million in ANX-530 sales.
Sorry, but a conclusion like that strains credibility.
In the real world, doctors in the U.S. do not use very much vinorelbine to treat non-small cell lung cancer patients, which is why sales are so low. The preferred chemotherapy regimen here is a combination of carboplatin and paclitaxel. (Vinorelbine is used more in Europe.)
Vinorelbine is very cheap and vein irritation occurs in only about 30% of patients, so it's not a huge problem. ANX-530 is simply not differentiated enough for doctors to switch, especially since ANX-530 will cost more. (Perhaps a lot more if Culley prices the drug based on his market research.)
Adventrx also has problems with its second pipeline drug, a reformulation of the chemotherapy drug docetaxel known as ANX-514.
Docetaxel, sold under the brand name Taxotere by Sanofi-Aventis, is a $3 billion-dollar chemotherapy drug, so Adventrx is targeting a very lucrative commercial market.
Unfortunately, Adventrx has not established crystal-clear bioequivalence between ANX-514 and docetaxel based on the results from the company's small pharmacokinetic study. Culley concedes that he can't file for approval based on the data he has so far. The company is going to meet with the FDA to establish next steps, which may involve more clinical trials. (Culley is hoping that this isn't necessary but he certainly can't guarantee it.)
The other problem for ANX-514 is that there are no data conclusively showing any favorable benefit -- safety, efficacy or tolerability -- over docetexal. Culley says that doctors might infer that ANX-514, which lacks the detergents contained in docetaxel, causes less hypersensitivity reactions in patients, but he says the company has no conclusive data to make that claim.
And let's not forget that the branded patent life on docetaxel is rapidly coming to a close. Cheap, generic docetaxel could hit the market as early as this spring, if generic drugmakers win court challenges. If not, generic docetaxel will definitely hit the market in 2013. Adventrx is simply running out of time.
One last thing: Yes, billionaire investor Carl Icahn does own a considerable stake in Adventrx, but it's important to understand that Icahn bought his position years ago before CoFactor failed (and at a much higher price.) Icahn's biotech lieutenant Alex Denner used to sit on Adventrx's board, but no longer.
"I recognize the buzz that comes from Icahn owning our stock, but it's a passive position," Culley says.
Nice info. I was in @ .41 and sold @ .37. Got impatient.
I still believe this is a good entry. No dry powder right now.
GLTU
Here we go
HOD coming up next
Feels like it's gonna start running at .69 any second now.
feels like a breakout comming.
She be rockin here folks.
Where is ya?
DARA In a definite uptrend
edit.
IMGG taking a nose dive. I guess the conf. call didn't go so well.
Might be a good buying opp. comming up in the next few sessions.
I looked out into the San Fransisco bay this morning, and Saw Cully walking across it. The man can walk on water.
Buy=Buy=Buy
Nice bump on BNVI this am. SNSS moving up as well.
not much. Riding ANX from .17 APP from 2.60 and ARDM from .14
how bout u?
I'm all for it. lol
Perhaps Carl Ichan's outlook is more long term than yours or mine.
He has owned ANX for quite some time.
And, he has a pretty good track record.
GLTU
ANX alerted here @ .17 printed HOY .52 today. Still got a double left in her.
Check out the ANX IBOX
Dude, thats a pretty chart. I own some of that. hehehehehehehehe
WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
Go to the IBOX. And read the filing. All the info is there.
Thanks to Camaro. And Thank you Camaro.
61 mil shares and a 2% gain. I would say there is a little intrest here. Okay, alot of intrest here.lol
Hold on tight.
Glad to see you here Timmage. You were 1 of the first conversations I had on IHUB. NTWK I am well aware of what your about.
Brings a scence of calm to me to see you here.
Best of luck to you.
NEXM going off. ANX's turn tomorrow.
MedaSorb Technologies Corporation to Present at the Biotech Showcase(TM) 2010
Date : 01/11/2010 @ 3:48PM
Source : MarketWire
Stock : MedaSorb Technologies Corporation
(MSBT)
Quote : 0.21 0.0 (0.00%) @ 7:55AM
MedaSorb Technologies Corporation to Present at the Biotech Showcase(TM) 2010
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 01/11/10 --
MedaSorb Technologies Corporation (OTCBB: MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., announced that Dr. Phillip Chan, Chief Executive Officer, will present at Biotech Showcase(TM) 2010 on Tuesday, January 12, 2010 in San Francisco
The presentation will take place at 8:00AM PST in the Crystal Lounge on the 11th Floor at the Marines' Memorial Club & Hotel
http://www.ebdgroup.com/bts/
An audio webcast of the slide presentation will be available by Thompson Reuters http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MSBT&item_id=2674413
An electronic copy of the presentation will be made available upon email request following the presentation
About MedaSorb, CytoSorbents and CytoSorb(TM)
MedaSorb Technologies Corporation, and its operating subsidiary CytoSorbents, is a therapeutic device company in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb(TM). Severe sepsis is typically caused by bacterial infections like pneumonia, or viral infections like influenza
It afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Much of the organ failure and mortality in severe sepsis is caused by the abnormal massive production of cytokines by the immune system, often called "cytokine storm." CytoSorb(TM) is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped through the CytoSorb(TM) cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb(TM) in the European Union in 2010
CytoSorb(TM) is one of a number of different resins designed for different medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, treatment of rhabdomyolysis in trauma, drug detoxification and others
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-KSB filed with the SEC on April 10, 2009, which is available at http://www.sec.gov
Contact: CytoSorbents, Inc David Lamadrid (732) 329-8885 ext. 816 davidl@cytosorbents.com
Imaging3 to Host Conference Call Regarding FDA Status
Date : 01/11/2010 @ 4:33PM
Source : MarketWire
Stock : Imaging3, Inc. (IMGG)
Quote : 0.72 0.0 (0.00%) @ 2:05AM
Imaging3 to Host Conference Call Regarding FDA Status
BURBANK, CA -- (Marketwire) -- 01/11/10 --
Imaging3(TM), Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Tuesday, January 12, 2010 at 1:00pm PST (4:00pm EST), the company's CEO, Mr. Dean Janes, will be hosting a conference call. To join the conference call, please call 1-877-757-0918 and enter passcode 681029 followed by the pound sign (#). You will be connected to the conference call in a listen only mode, and then lines will be opened for questions following the presentation
The purpose of the call is to update Shareholders and other interested parties of the current developments with the company's 510k FDA submission
Currently the FDA has requested further information and Mr. Janes would like to discuss the company's plans to address these questions
A recording of the conference call will be made available on the company's website as soon as it is available. Imaging3 will notify shareholders and others who are on the company's e-mail opt-in list. Anyone who would like to be added to this list is encouraged to sign-up for the e-mail based newsletter on the company's website using the following link -- http://www.imaging3.com/newsletters_signup.html
About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at http://www.imaging3.com for more information
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company
Contact: Imaging3, Inc
Investor Relations 800-900-9729
Good morning all. Where are we heading today? Hope the upward trend continues. My .17's are looking mighty sweet here.